Skip to Content

22,839 Results Found

  • Article
  • Open Access
5 Citations
5,533 Views
15 Pages

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC

  • Guang-Ling Jie,
  • Lun-Xi Peng,
  • Mei-Mei Zheng,
  • Hao Sun and ,
  • Song-Rong Wang,
  • Si-Yang Maggie Liu,
  • Kai Yin,
  • Zhi-Hong Chen,
  • Hong-Xia Tian and
  • Yi-Long Wu
  • + 10 authors+ 5 authors

1 January 2023

MET inhibitors have shown promising efficacy for MET-dysregulated non-small cell lung cancer (NSCLC). However, quite a few patients cannot benefit from it due to the lack of powerful biomarkers. This study aims to explore the potential role of plasma...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Review
  • Open Access
13 Citations
3,942 Views
17 Pages

MET Oncogene Targeting for Cancer Immunotherapy

  • Andrea Maria Lombardi,
  • Dario Sangiolo and
  • Elisa Vigna

The MET receptor is one of the main drivers of ‘invasive growth’, a multifaceted biological response essential during embryonic development and tissue repair that is usurped by cancer cells to induce and sustain the malignant phenotype. M...

(This article belongs to the Special Issue Update on Immunotherapies for Cancer)
  • Review
  • Open Access
20 Citations
6,997 Views
17 Pages

Met in Urological Cancers

  • Yasuyoshi Miyata,
  • Akihiro Asai,
  • Kensuke Mitsunari,
  • Tomohiro Matsuo and ,
  • Kojiro Ohba,
  • Yasushi Mochizuki and
  • Hideki Sakai
  • + 2 authors+ 0 author

16 December 2014

Met is a tyrosine kinase receptor that is considered to be a proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis in many types of malignancies. Furthermore, Met ex...

(This article belongs to the Special Issue MET in Cancer)
  • Review
  • Open Access
1 Citations
1,826 Views
23 Pages

MET pathway alterations have evolved from a niche translational interest into one of the most clinically actionable axes in non-small cell lung cancer (NSCLC). Three biologically distinct lesions—MET exon 14 (METex14) skipping mutations, focal...

(This article belongs to the Section Materials Science)
  • Article
  • Open Access
4 Citations
3,610 Views
20 Pages

Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma

  • Eric Santoni-Rugiu,
  • Maya Jeje Schuang Lü,
  • Jan Nyrop Jakobsen,
  • Linea Cecilie Melchior and ,
  • Jesper Ravn and
  • Jens Benn Sørensen
  • + 1 author+ 0 author

28 November 2021

Thanks to clinically newly introduced inhibitors of the mesenchymal–epithelial transition (MET) receptor tyrosine-kinase, MET-gene copy number gain/amplification (MET-GCNG/GA) and increased expression of the MET protein are considered very prom...

(This article belongs to the Special Issue Molecular Players in Diagnostics and Therapeutics of Malignant Pleural Mesothelioma)
  • Article
  • Open Access
4 Citations
3,257 Views
13 Pages

Capmatinib and savolitinib, selective MET inhibitors, are widely used to treat various MET-positive cancers. In this study, we aimed to determine the effects of these inhibitors on MET-amplified gastric cancer (GC) cells. Methods: After screening 37...

(This article belongs to the Section Molecular Oncology)
  • Review
  • Open Access
21 Citations
4,954 Views
14 Pages

Overview of Molecular Detection Technologies for MET in Lung Cancer

  • Carina Heydt,
  • Michaela Angelika Ihle and
  • Sabine Merkelbach-Bruse

26 May 2023

MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET exon 14 sk...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Article
  • Open Access
13 Citations
6,324 Views
23 Pages

Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer

  • Jooseok Kim,
  • Kyung Eui Park,
  • Yoo-Seong Jeong,
  • YeongMun Kim and ,
  • Hayeon Park,
  • Ji-Hye Nam,
  • Kyungsoo Jung,
  • Woo Sung Son,
  • Hun Soon Jung and
  • Young Kee Shin
  • + 14 authors+ 9 authors

15 June 2020

The receptor tyrosine kinase c-MET regulates processes essential for tissue remodeling and mammalian development. The dysregulation of c-MET signaling plays a role in tumorigenesis. The aberrant activation of c-MET, such as that caused by gene amplif...

  • Article
  • Open Access
11 Citations
5,324 Views
13 Pages

MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome

  • Wei Yin,
  • Ming Guo,
  • Zhenya Tang,
  • Gokce A. Toruner and ,
  • Joanne Cheng,
  • L. Jeffrey Medeiros and
  • Guilin Tang
  • + 2 authors+ 0 author

14 May 2022

MET amplification has been associated with shorter survival in cancer patients, however, the potential correlation of MET overexpression with either MET amplification or patient outcome is controversial. The aim of this study was to address these que...

(This article belongs to the Topic The Role of Transmembrane Mucins in Lung Diseases)
  • Guidelines
  • Open Access
7 Citations
7,477 Views
25 Pages

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC

  • Parneet K. Cheema,
  • Shantanu O. Banerji,
  • Normand Blais,
  • Quincy S.-C. Chu and ,
  • Patrice Desmeules,
  • Rosalyn A. Juergens,
  • Natasha B. Leighl,
  • Brandon S. Sheffield,
  • Paul F. Wheatley-Price and
  • Barbara L. Melosky
  • + 5 authors+ 0 author

9 November 2021

In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatment...

  • Review
  • Open Access
20 Citations
6,586 Views
14 Pages

14 September 2023

The MET gene plays a vital role in cellular proliferation, earning it recognition as a principal oncogene. Therapies that target MET amplification have demonstrated promising results both in preclinical models and in specific clinical cases. A signif...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Review
  • Open Access
8 Citations
6,836 Views
19 Pages

The MET Oncogene: An Update on Targeting Strategies

  • Simona Gallo,
  • Consolata Beatrice Folco and
  • Tiziana Crepaldi

2 November 2024

The MET receptor, commonly known as HGF (hepatocyte growth factor) receptor, is a focus of extensive scientific research. MET has been linked to embryonic development, tissue regeneration following injury, tumorigenesis, and cancer metastasis. These...

(This article belongs to the Section Pharmacology)
  • Review
  • Open Access
35 Citations
11,548 Views
16 Pages

MET and Small-Cell Lung Cancer

  • Francesco Gelsomino,
  • Giulio Rossi and
  • Marcello Tiseo

13 October 2014

Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invar...

(This article belongs to the Special Issue MET in Cancer)
  • Review
  • Open Access
24 Citations
6,866 Views
11 Pages

26 April 2022

Dysregulation of the MET tyrosine kinase receptor is a known oncogenic driver, and multiple genetic alterations can lead to a clinically relevant oncogenesis. Currently, a number of drugs targeting MET are under development as potential therapeutics...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Review
  • Open Access
13 Citations
8,796 Views
13 Pages

c-Met and miRs in Cancer

  • Simona Giglio and
  • Andrea Vecchione

c-Met, a member of the receptor tyrosine kinase family, is involved in a wide range of cellular processes, including tumor survival, cell growth, angiogenesis and metastasis, and resulting in overexpression in many human cancers, leading to a constit...

(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
  • Review
  • Open Access
11 Citations
6,836 Views
15 Pages

Cyclic Peptide-Based Biologics Regulating HGF-MET

  • Hiroki Sato,
  • Ryu Imamura,
  • Hiroaki Suga,
  • Kunio Matsumoto and
  • Katsuya Sakai

27 October 2020

Using a random non-standard peptide integrated discovery system, we obtained cyclic peptides that bind to hepatocyte growth factor (HGF) or mesenchymal-epithelial transition factor. (MET) HGF-inhibitory peptide-8 (HiP-8) selectively bound to two-chai...

(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF), II)
  • Review
  • Open Access
22 Citations
8,810 Views
23 Pages

29 April 2025

Background: Recent research has increasingly highlighted alterations in the proto-oncogene MET, whose abnormal activation has been implicated in multiple cancers. MET encodes c-MET, a receptor tyrosine kinase critical for cellular growth, survival, a...

(This article belongs to the Section Molecular Cancer Biology)
  • Article
  • Open Access
11 Citations
4,553 Views
16 Pages

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

  • Nam Ah Kim,
  • Sungyoul Hong,
  • Ki Hyun Kim,
  • Du Hyung Choi and ,
  • Joo Seok Kim,
  • Kyung Eui Park,
  • Jun Young Choi,
  • Young Kee Shin and
  • Seong Hoon Jeong
  • + 4 authors+ 0 author

c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially...

(This article belongs to the Special Issue Bioavailability Enhancement of Poorly Water-Soluble Drugs: Biopharmaceutics and Technology)
  • Article
  • Open Access
1 Citations
2,547 Views
17 Pages

Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination

  • Chiara Modica,
  • Marco Cortese,
  • Francesca Bersani,
  • Andrea Maria Lombardi and ,
  • Francesca Napoli,
  • Luisella Righi,
  • Riccardo Taulli,
  • Cristina Basilico and
  • Elisa Vigna
  • + 4 authors+ 0 author

13 May 2023

Cancer cell dissemination is sustained by cell-autonomous and non-cell-autonomous functions. To disentangle the role of HGF (Hepatocyte Growth Factor) and MET ligand/receptor axis in this complex process, we genetically knocked out the MET gene in ca...

(This article belongs to the Special Issue The Biological Mechanism of Cancer Proliferation and Metastasis)
  • Review
  • Open Access
9 Citations
4,506 Views
23 Pages

21 September 2023

The MET proto-oncogene encodes a pivotal tyrosine kinase receptor, binding the hepatocyte growth factor (HGF, also known as scatter factor, SF) and governing essential biological processes such as organogenesis, tissue repair, and angiogenesis. The p...

(This article belongs to the Section Molecular Cancer Biology)
  • Review
  • Open Access
8 Citations
6,925 Views
19 Pages

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma

  • Joycelyn J. X. Lee,
  • Jack J. Chan and
  • Su Pin Choo

28 October 2015

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improve...

(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
  • Review
  • Open Access
96 Citations
13,507 Views
13 Pages

Targeting MET Amplification as a New Oncogenic Driver

  • Hisato Kawakami,
  • Isamu Okamoto,
  • Wataru Okamoto,
  • Junko Tanizaki and ,
  • Kazuhiko Nakagawa and
  • Kazuto Nishio
  • + 1 author+ 0 author

22 July 2014

Certain genetically defined cancers are dependent on a single overactive oncogene for their proliferation and survival, a phenomenon known as “oncogene addiction”. A new generation of drugs that selectively target such “driver oncogenes” manifests a...

(This article belongs to the Special Issue MET in Cancer)
  • Review
  • Open Access
92 Citations
11,677 Views
17 Pages

3 December 2018

Hepatocyte growth factor (HGF)/ mesenchymal-epithelial transition factor (c-MET) signaling is involved in complex cellular programs that are important for embryonic development and tissue regeneration, but its activity is also utilized by cancer cell...

(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF))
  • Article
  • Open Access
31 Citations
5,054 Views
13 Pages

c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer

  • Chung Hyo Kang,
  • Yeongrin Kim,
  • Da Yeon Lee,
  • Sang Un Choi and ,
  • Heung Kyoung Lee and
  • Chi Hoon Park
  • + 1 author+ 0 author

16 November 2021

Chimeric antigen receptor (CAR) technology has been highlighted in recent years as a new therapeutic approach for cancer treatment. Although the impressive efficacy of CAR-based T cell adoptive immunotherapy has been observed in hematologic cancers,...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
8 Citations
3,988 Views
12 Pages

15 July 2022

Both MET exon 14 skipping mutation (METex14SM) and high copy-number variation (CNV) lead to enhanced carcinogenesis; additionally, programmed-death ligand 1 (PD-L1) is often upregulated in cancers. In this study, we characterized the expression of ME...

(This article belongs to the Section Cancer Pathophysiology)
  • Review
  • Open Access
33 Citations
5,283 Views
15 Pages

The Role of HGF/MET Signaling in Metastatic Uveal Melanoma

  • Ryota Tanaka,
  • Mizue Terai,
  • Eric Londin and
  • Takami Sato

30 October 2021

Hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signaling promotes tumorigenesis and tumor progression in various types of cancer, including uveal melanoma (UM). The roles of HGF/MET signaling have been studied in cell s...

(This article belongs to the Special Issue Metastatic Uveal Melanoma)
  • Article
  • Open Access
1 Citations
1,704 Views
15 Pages

Phosphorylation of MET Is Upregulated in Metastatic Sites of Renal Cell Carcinoma: Possible Role of MET and Hepatocyte Growth Factor Activation-Targeted Combined Therapy

  • Takahiro Akioka,
  • Shoichi Kimura,
  • Yuichi Katayama,
  • Masato Fujii and ,
  • Takumi Kiwaki,
  • Makiko Kawaguchi,
  • Tsuyoshi Fukushima,
  • Yuichiro Sato,
  • Shoichiro Mukai and
  • Atsuro Sawada
  • + 6 authors+ 1 author

Background: Increased expression of MET and hepatocyte growth factor (HGF)-related molecules has been positively correlated with poor prognosis in renal cell carcinoma (RCC). In the current study, the expression and phosphorylation of MET in metastat...

(This article belongs to the Section Cancer Biology and Oncology)
  • Review
  • Open Access
9 Citations
7,151 Views
22 Pages

MET Activation in Lung Cancer and Response to Targeted Therapies

  • Sarah Anna Okun,
  • Daniel Lu,
  • Katherine Sew,
  • Asha Subramaniam and
  • William W. Lockwood

16 January 2025

The hepatocyte growth factor receptor (MET) is a receptor tyrosine kinase (RTK) that mediates the activity of a variety of downstream pathways upon its activation. These pathways regulate various physiological processes within the cell, including gro...

(This article belongs to the Special Issue New and Emerging Strategies for Targeting Genomic Instability and Overcoming Drug Resistance in Lung Cancer)
  • Review
  • Open Access
9 Citations
5,562 Views
26 Pages

The MET Oncogene Network of Interacting Cell Surface Proteins

  • Simona Gallo,
  • Consolata Beatrice Folco and
  • Tiziana Crepaldi

21 December 2024

The MET oncogene, encoding the hepatocyte growth factor (HGF) receptor, plays a key role in tumorigenesis, invasion, and resistance to therapy, yet its full biological functions and activation mechanisms remain incompletely understood. A feature of M...

(This article belongs to the Special Issue Latest Review Papers in Molecular and Cellular Biology 2024)
  • Feature Paper
  • Review
  • Open Access
3 Citations
8,350 Views
33 Pages

MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing

  • Kenneth Kin-Wah To,
  • Kwong-Sak Leung and
  • William Chi-Shing Cho

The Met protein is a cell surface receptor tyrosine kinase predominantly expressed in epithelial cells. Aberrant regulation of MET is manifested by numerous mechanisms including amplification, mutations, deletion, fusion of the MET proto-oncogene, an...

(This article belongs to the Section Preclinical Research)
  • Review
  • Open Access
26 Citations
7,168 Views
25 Pages

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target

  • Gianluca Spitaleri,
  • Pamela Trillo Aliaga,
  • Ilaria Attili,
  • Ester Del Signore and ,
  • Carla Corvaja,
  • Chiara Corti,
  • Jacopo Uliano,
  • Antonio Passaro and
  • Filippo de Marinis
  • + 4 authors+ 0 author

28 September 2023

Non-Small-Cell Lung Cancer (NSCLC) can harbour different MET alterations, such as MET overexpression (MET OE), MET gene amplification (MET AMP), or MET gene mutations. Retrospective studies of surgical series of patients with MET-dysregulated NSCLC h...

(This article belongs to the Special Issue Cancer Therapy: Where We Are and Where We Need to Go)
  • Review
  • Open Access
49 Citations
14,618 Views
16 Pages

HGF/Met Axis in Heart Function and Cardioprotection

  • Simona Gallo,
  • Valentina Sala,
  • Stefano Gatti and
  • Tiziana Crepaldi

21 October 2014

Hepatocyte growth factor (HGF) and its tyrosine kinase receptor (Met) play important roles in myocardial function both in physiological and pathological situations. In the developing heart, HGF influences cardiomyocyte proliferation and differentiat...

(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
  • Article
  • Open Access
4 Citations
3,926 Views
15 Pages

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody

  • Chiara Modica,
  • Simona Gallo,
  • Cristina Chiriaco,
  • Martina Spilinga and ,
  • Paolo Maria Comoglio,
  • Tiziana Crepaldi,
  • Cristina Basilico and
  • Elisa Vigna
  • + 3 authors+ 0 author

21 March 2020

The MET oncogene encodes a tyrosine kinase receptor involved in the control of a complex network of biological responses that include protection from apoptosis and stimulation of cell growth during embryogenesis, tissue regeneration, and cancer progr...

(This article belongs to the Special Issue Cell Death in Cancer)
  • Review
  • Open Access
40 Citations
7,442 Views
18 Pages

HGF/MET Signaling in Malignant Brain Tumors

  • Elizabeth Qian Xu Mulcahy,
  • Rossymar Rivera Colόn and
  • Roger Abounader

13 October 2020

Hepatocyte growth factor (HGF) ligand and its receptor tyrosine kinase (RTK) mesenchymal-epithelial transition factor (MET) are important regulators of cellular processes such as proliferation, motility, angiogenesis, and tissue regeneration. In heal...

(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF), II)
  • Article
  • Open Access
12 Citations
4,402 Views
11 Pages

Correlation of MET and PD-L1 Expression in Malignant Melanoma

  • Kyu Young Song,
  • Sabina Desar,
  • Thomas Pengo,
  • Ryan Shanley and
  • Alessio Giubellino

9 July 2020

The proto-oncogene MET, the hepatocyte growth factor (HGF) receptor, is a transmembrane receptor tyrosine kinase (RTK) with a prominent role in tumor metastasis and resistance to anti-cancer therapies. Melanoma demonstrates relatively frequent MET ab...

(This article belongs to the Section Cancer Biomarkers)
  • Article
  • Open Access
28 Citations
5,910 Views
18 Pages

Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

  • Patricia Mondelo-Macía,
  • Carmela Rodríguez-López,
  • Laura Valiña,
  • Santiago Aguín and ,
  • Luis León-Mateos,
  • Jorge García-González,
  • Alicia Abalo,
  • Oscar Rapado-González,
  • Mercedes Suárez-Cunqueiro and
  • Rafael López-López
  • + 13 authors+ 8 authors

24 February 2020

MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alte...

(This article belongs to the Special Issue Liquid Biopsy)
  • Review
  • Open Access
4 Citations
3,698 Views
12 Pages

20 July 2024

The development and growth of cancer is fundamentally dependent on pro-tumor changes in metabolism. Cancer cells generally shift away from oxidative phosphorylation as the primary source of energy and rely more heavily on glycolysis. Receptor tyrosin...

(This article belongs to the Section Molecular Genetics and Genomics)
  • Review
  • Open Access
29 Citations
15,301 Views
39 Pages

12 August 2014

Met is the receptor of hepatocyte growth factor (HGF), a cytoprotective cytokine. Disturbing the equilibrium between Met and its ligand may lead to inappropriate cell survival, accumulation of genetic abnormalities and eventually, malignancy. Abnorma...

(This article belongs to the Special Issue MET in Cancer)
  • Review
  • Open Access
71 Citations
9,180 Views
18 Pages

Targeting HGF/c-MET Axis in Pancreatic Cancer

  • Srinivasa P. Pothula,
  • Zhihong Xu,
  • David Goldstein,
  • Romano C. Pirola and ,
  • Jeremy S. Wilson and
  • Minoti V. Apte
  • + 1 author+ 0 author

1 December 2020

Pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC/PC)) has been an aggressive disease that is associated with early metastases. It is characterized by dense and collagenous desmoplasia/stroma, predominantly produced by pancreatic stellate cel...

(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF), II)
  • Review
  • Open Access
64 Citations
9,489 Views
16 Pages

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma

  • Nichola Cruickshanks,
  • Ying Zhang,
  • Fang Yuan,
  • Mary Pahuski and ,
  • Myron Gibert and
  • Roger Abounader
  • + 1 author+ 0 author

11 July 2017

Glioblastoma (GBM) is a lethal brain tumor with dismal prognosis. Current therapeutic options, consisting of surgery, chemotherapy and radiation, have only served to marginally increase patient survival. Receptor tyrosine kinases (RTKs) are dysregula...

(This article belongs to the Special Issue Hepatocyte Growth Factor Pathway in Cancer)
  • Review
  • Open Access
88 Citations
16,274 Views
26 Pages

HGF–Met Pathway in Regeneration and Drug Discovery

  • Kunio Matsumoto,
  • Hiroshi Funakoshi,
  • Hisaaki Takahashi and
  • Katsuya Sakai

31 October 2014

Hepatocyte growth factor (HGF) is composed of an α-chain and a β-chain, and these chains contain four kringle domains and a serine protease-like structure, respectively. Activation of the HGF–Met pathway evokes dynamic biological responses that supp...

(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
  • Article
  • Open Access
33 Citations
10,203 Views
13 Pages

VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells

  • Raimond Heukers,
  • Vida Mashayekhi,
  • Mercedes Ramirez-Escudero,
  • Hans de Haard and ,
  • Theo C. Verrips,
  • Paul. M.P. van Bergen en Henegouwen and
  • Sabrina Oliveira
  • + 2 authors+ 0 author

Photodynamic therapy (PDT) is an approach that kills (cancer) cells by the local production of toxic reactive oxygen species upon the local illumination of a photosensitizer (PS). The specificity of PDT has been further enhanced by the development of...

(This article belongs to the Special Issue Nanobody)
  • Article
  • Open Access
4 Citations
2,618 Views
15 Pages

SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer

  • Katia De Marco,
  • Martina Lepore Signorile,
  • Elisabetta Di Nicola,
  • Paola Sanese and ,
  • Candida Fasano,
  • Giovanna Forte,
  • Vittoria Disciglio,
  • Antonino Pantaleo,
  • Greta Varchi and
  • Cristiano Simone
  • + 7 authors+ 2 authors

18 October 2023

Gastric cancer (GC) is the third most deadly cancer worldwide. Considerable efforts have been made to find targetable drivers in order to improve patient outcomes. MET is one of the most important factors involved in GC initiation and progression as...

(This article belongs to the Section Tissues and Organs)
  • Review
  • Open Access
96 Citations
8,448 Views
13 Pages

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

  • Federica Papaccio,
  • Carminia Maria Della Corte,
  • Giuseppe Viscardi,
  • Raimondo Di Liello and ,
  • Giovanna Esposito,
  • Francesca Sparano,
  • Fortunato Ciardiello and
  • Floriana Morgillo
  • + 3 authors+ 0 author

14 November 2018

An overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) axis promotes tumorigenesis and tumor progression in various cancer types. Research data recently evidenced that HGF/MET signaling is also involved als...

(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF))
  • Communication
  • Open Access
4 Citations
1,767 Views
10 Pages

MET and SLFN11 as a Players in the SCLC Molecular Subtyping Game

  • Anna Grenda,
  • Natalia Galant,
  • Aleksandra Łomża-Łaba,
  • Paweł Krawczyk and ,
  • Tomasz Jankowski,
  • Izabela Chmielewska,
  • Michał Szczyrek,
  • Robert Kieszko and
  • Janusz Milanowski
  • + 4 authors+ 0 author

The possibilities of small-cell lung cancer (SCLC) therapy were strictly limited for years, leading to high patient mortality rates. New approaches to SCLC treatment are being proposed, including chemoimmunotherapy. However, biomarkers enabling appro...

(This article belongs to the Section Molecular Oncology)
  • Review
  • Open Access
16 Citations
12,205 Views
18 Pages

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis

  • Giovanni Gaudino,
  • Haining Yang and
  • Michele Carbone

14 November 2014

Malignant mesothelioma (MM) is a highly aggressive cancer related to asbestos or erionite exposure and resistant to current therapies. Hepatocyte Growth Factor (HGF) and its tyrosine kinase receptor Met regulate cell growth, survival, motility/migrat...

(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
  • Article
  • Open Access
5 Citations
4,110 Views
16 Pages

MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer

  • Yu-Min Yeh,
  • Pei-Ying Wu,
  • Peng-Chan Lin,
  • Pei-Fang Su and ,
  • Ya-Ting Hsu,
  • Keng-Fu Hsu and
  • Meng-Ru Shen
  • + 2 authors+ 0 author

23 August 2021

An optimal therapeutic regimen for endometrial cancer with extra-uterine metastasis is unavailable. This study aims to improve our understanding of the genomic landscape of advanced endometrial cancer and identify potential therapeutic targets. The c...

  • Review
  • Open Access
45 Citations
8,970 Views
17 Pages

HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers

  • Hongli Zhang,
  • Qingqing Feng,
  • Wei-Dong Chen and
  • Yan-Dong Wang

23 October 2018

The HGF/c-MET pathway is active in the development of digestive system cancers, indicating that inhibition of HGF/c-MET signaling may have therapeutic potential. Various HGF/c-MET signaling inhibitors, mainly c-MET inhibitors, have been tested in cli...

(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF))
  • Review
  • Open Access
27 Citations
8,441 Views
18 Pages

25 January 2024

Brain tumors represent a heterogeneous group of neoplasms characterized by a high degree of aggressiveness and a poor prognosis. Despite recent therapeutic advances, the treatment of brain tumors, including glioblastoma (GBM), an aggressive primary b...

(This article belongs to the Special Issue Novel Therapeutic Strategies for the Treatment of Brain Tumors)
  • Review
  • Open Access
68 Citations
16,421 Views
22 Pages

Activated HGF-c-Met Axis in Head and Neck Cancer

  • Levi Arnold,
  • Jonathan Enders and
  • Sufi Mary Thomas

12 December 2017

Head and neck squamous cell carcinoma (HNSCC) is a highly morbid disease. Recent developments including Food and Drug Administration (FDA) approved molecular targeted agent’s pembrolizumab and cetuximab show promise but did not improve the five-year...

(This article belongs to the Special Issue Hepatocyte Growth Factor Pathway in Cancer)

of 457